Evidence-Grading Methodology

This page is the backbone of everything we publish. Every efficacy or safety statement attached to a peptide on Peptevity carries an evidence grade. The grade is not our opinion about whether a compound "works." It is a transparent label for how strong the underlying research is, and in which species it was conducted. This is the single most important thing to understand about how to read this site: a high grade means the evidence is strong, not that the compound is safe, legal, or appropriate for any person.

This is research and educational information, not medical advice. Nothing here is an endorsement of human use. Many peptides we cover are not approved by the FDA for any human use and are sold only as "research use only" materials labeled not for human consumption — see our medical disclaimer and RUO statement.

Why we grade evidence at all

The peptide information landscape is split between two failure modes. Vendors overstate — "miracle healing," "wolverine peptide," "reverses aging" — because they profit from the claim. Some gatekeepers understate, issuing a blanket "just don't" that flattens a strong-human-trial compound and a single-mouse-study compound into the same warning. Neither tells you what you actually came to find out: what does the research show, in what species, and how confident can anyone honestly be?

Grading forces that question to be answered on the surface of every page. It also lets us do the one thing the conflicted sources cannot do credibly: say "the animal data is strong and there are no human trials" plainly, and assign that statement a grade that any reader — or any large language model citing us — can verify against the linked primary source.

The six grades

Peptevity assigns one of six grades to each material claim. Grades describe the body of evidence behind a specific claim, not the compound as a whole. A single peptide will usually carry different grades for different claims (for example, a B for one outcome and an E for another).

Grade A — Strong human evidence

Definition. Multiple well-designed randomized controlled trials (RCTs) in humans, or a systematic review / meta-analysis of such trials, support the claim. Results are consistent across studies, sample sizes are adequate, and the finding is not contradicted by higher-quality work.

What it looks like in practice. This grade is largely reserved for the FDA-approved peptides and their established indications — for example, the glycemic and weight outcomes of semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound), which rest on large registrational Phase 3 trial programs. Most "research peptides" never reach this tier because the human trials simply do not exist.

What an A does not mean. It does not extend to off-label uses, compounded versions, or research-grade material of the same molecule. The grade is attached to the specific claim and the specific evidence, not to the molecule's name.

Grade B — Limited or emerging human evidence

Definition. One or more human studies support the claim, but the body of evidence is limited — small samples, single trials, early-phase work, surrogate endpoints, short follow-up, or results not yet replicated. The direction of evidence is real and human, but it is not yet settled.

What it looks like in practice. Early-phase clinical results for a compound still in development, or a single published human trial for a topical or injectable peptide. Retatrutide's published Phase 2 weight-loss data, for example, is genuine human evidence — but it is earlier-stage and narrower than the approved GLP-1 programs, so a claim resting on it grades B rather than A. We will say "human data exists but is limited and early" rather than implying it is established.

Grade C — Animal-only evidence

Definition. The claim is supported by in-vivo studies in animals (typically rodents), with no qualifying human trials for that outcome. The biology may be promising and the animal data may even be robust, but it has not been tested in people.

What it looks like in practice. This is the home grade for much of the healing-peptide catalog. Many of the most-cited BPC-157 tendon, ligament, and gut findings are rat studies; the human RCT literature for those outcomes is effectively absent. When we describe such a finding we will write "studies in rats suggest…" or "in a rat model…", never "BPC-157 heals tendons." A strong C is still a C: animal evidence does not transfer to humans by default.

Grade D — In-vitro / mechanistic evidence

Definition. Support comes from cell-culture (in-vitro), biochemical, or purely mechanistic work — receptor binding, pathway activation, effects on cultured cells — with no whole-animal or human outcome data for the claim.

What it looks like in practice. "Compound X upregulates collagen synthesis in cultured fibroblasts" or "X activates the Y receptor." This tells you a plausible mechanism exists; it tells you nothing about whether the effect occurs, helps, or is safe in a living organism. We flag mechanistic claims explicitly so they are never mistaken for outcomes.

Grade E — Anecdotal / unverified

Definition. The claim rests on user reports, forum and Reddit testimony, vendor marketing, practitioner anecdote, or other non-systematic sources, with no controlled study of any kind.

What it looks like in practice. "Users report faster recovery." We will sometimes note that a claim is widely repeated anecdotally — because acknowledging the folk reputation is part of being an honest broker — but we grade it E and say so. Anecdote is the floor, not evidence of effect. We never launder a Grade E claim into something that reads like a finding.

Grade F — Contradicted / no credible evidence

Definition. The best available evidence contradicts the claim, or the claim has been specifically examined and not supported. This grade is also used when a popular claim collapses on inspection.

What it looks like in practice. A marketed benefit that a controlled study failed to reproduce, or a "reverses aging" claim with no credible support. We assign F sparingly and only with a citation to the contradicting source, because "no evidence yet" (often a C or D situation) is not the same as "evidence against."

The grade is independent of safety and legality

This is the most misread part of the rubric, so we state it bluntly: the evidence grade is orthogonal to safety and to legal status. A Grade A claim can attach to a compound with serious documented risks. A Grade C compound can be entirely unapproved and sold only as research material not for human consumption. A high evidence grade is never a green light.

Because of this, every compound monograph on Peptevity carries three separate, prominently displayed signals, and they must never be collapsed into one:

1. Evidence grade (per claim) — how strong the research is, this page.
2. Regulatory status — the compound's current FDA approval / "research use only" / "not for human consumption" status, with a date. See our medical disclaimer and RUO framing.
3. Safety summary — documented adverse effects and unknowns, graded on the same evidence scale.

A reader should be able to encounter "Grade A evidence, FDA-approved, well-characterized safety profile" on one page and "Grade C evidence, not FDA-approved, safety in humans largely unstudied" on another, and immediately see that these are very different situations.

How a grade gets assigned (the procedure)

We apply the rubric the same way every time so that grades are reproducible, not vibes:

1. Isolate the specific claim. "Helps tendon healing" and "is safe long-term" are two claims and get two grades.
2. Find the highest-quality primary evidence for that claim. We search PMC/PubMed and the relevant trial registries first. We cite the primary study or a peer-reviewed systematic review — not a vendor blog, and not another secondary site. See our sourcing and citation policy.
3. Classify by the best available evidence — and by species. The grade is set by the strongest qualifying evidence, with the animal-vs-human distinction baked into the tier itself (A/B are human; C is animal; D is in-vitro).
4. Check for contradiction. If higher-quality work contradicts the claim, the grade is capped or moved to F, with the contradicting source cited.
5. Write the claim hedged and attributed. The on-page sentence must match the grade: "no human RCTs exist" for a C, "limited early human data" for a B, "supported by multiple RCTs" for an A.
6. Date it and schedule review. Each graded claim carries a last-reviewed date. The evidence base moves — especially for compounds in active development — so grades can change. When they do, the change is logged per our corrections policy.

Frequently asked questions

Does a Grade A peptide mean it is safe for me to use? No. The evidence grade measures only how strong the research behind a specific claim is. It says nothing about safety, legality, or whether a compound is appropriate for any individual. Safety and regulatory status are tracked separately on every page, and Peptevity does not give medical advice or dosing instructions. Decisions about use belong with a licensed physician.

What does "animal-only evidence" (Grade C) actually mean? It means the claim is supported by studies in animals — usually rats or mice — and that no qualifying human trials exist for that outcome. Animal results do not reliably transfer to humans. A strong body of rodent data is still Grade C, and we will say "studies in rats suggest" rather than stating the effect as a human fact.

Why do you grade individual claims instead of whole compounds? Because a single peptide can have strong human evidence for one outcome and nothing but cell-culture data for another. Grading the whole compound with one label would hide exactly the nuance a careful reader needs. We attach a grade to each material claim and link each to its primary source.

Can a grade change? Yes. Grades reflect the evidence available on the last-reviewed date. New trials, replications, or contradicting studies can move a grade up or down. Material grade changes are documented under our corrections policy so the change history is transparent.

How is this different from Examine.com's grading? We share the same core philosophy — grade the evidence, distinguish human from animal, cite the primary source. Our scope differs: we extend evidence-graded monographs across the full therapeutic and research-peptide catalog and pair every grade with a dated, vendor-neutral regulatory-status read. We link to Examine as a peer source where their coverage overlaps ours.

Related editorial standards

• Editorial standards — how we write, structure, and label every page.
• Sourcing and citation policy — which sources we cite and which we never do.
• Conflict-of-interest and funding — why we sell nothing and link to no vendors.
• Corrections policy — how we fix and log errors and grade changes.
• Medical disclaimer and RUO statement — research-use-only and not-medical-advice framing.
• The Peptevity Research Desk — who writes this and the reserved reviewer slot.

External references: evidence-grading concepts here are consistent with standard research hierarchies described by the U.S. National Library of Medicine / PubMed and discussed by Examine.com. Regulatory definitions referenced throughout are drawn from the U.S. Food and Drug Administration.